2026-525234-39-00RecruitingPhase 1
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Janssen Cilag International17 sites in 5 countries175 target enrollmentStarted: June 30, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Janssen Cilag International
- Enrollment
- 175
- Locations
- 17
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CTIS Point of Contact
Scientific
Janssen Cilag International
Study Sites (17)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma2024-513439-25-00Janssen Cilag International15
Recruiting
Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's DiseaseCrohn DiseaseNCT07577843Janssen Research & Development, LLC460
Recruiting
Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT07577856Janssen Research & Development, LLC644
Not yet recruiting
Not Applicable
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric CancersColorectal Neoplasms, Gastrointestinal NeoplasmsjRCT2041260049260
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisArthritis, PsoriaticNCT07321873Janssen Research & Development, LLC240